Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.
L'article Sofinnova Partners raises 725 million euros for its Crossover II fund est apparu en premier sur Maddyness - Le média pour comprendre le économie demain.